[go: up one dir, main page]

CN114699561B - Calcium-doped material, bone repair material and preparation method thereof - Google Patents

Calcium-doped material, bone repair material and preparation method thereof Download PDF

Info

Publication number
CN114699561B
CN114699561B CN202111659702.7A CN202111659702A CN114699561B CN 114699561 B CN114699561 B CN 114699561B CN 202111659702 A CN202111659702 A CN 202111659702A CN 114699561 B CN114699561 B CN 114699561B
Authority
CN
China
Prior art keywords
calcium
based material
doped
bone repair
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111659702.7A
Other languages
Chinese (zh)
Other versions
CN114699561A (en
Inventor
郭跃明
王宗良
章培标
刘香笈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FOSHAN HOSPITAL OF TCM
Changchun Institute of Applied Chemistry of CAS
Original Assignee
FOSHAN HOSPITAL OF TCM
Changchun Institute of Applied Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FOSHAN HOSPITAL OF TCM, Changchun Institute of Applied Chemistry of CAS filed Critical FOSHAN HOSPITAL OF TCM
Priority to CN202111659702.7A priority Critical patent/CN114699561B/en
Publication of CN114699561A publication Critical patent/CN114699561A/en
Application granted granted Critical
Publication of CN114699561B publication Critical patent/CN114699561B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/45Phosphates containing plural metal, or metal and ammonium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/42Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
    • A61L27/425Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624Nanocapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/02Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/50Solid solutions
    • C01P2002/52Solid solutions containing elements as dopants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention provides a doped calcium-based material, which comprises a calcium-based material and Cu and Gd doped in the calcium-based material, wherein the molar ratio of the Cu to the Gd to Ca in the calcium-based material is 0.1-2. The invention also provides a preparation method of the doped calcium-based material and a bone repair material. According to the invention, cu and Gd are simultaneously added into the calcium-based material, wherein the Cu element has remarkable antibacterial property, anti-inflammatory property and immunoregulation property, and the doping of the Gd element is beneficial to improving the Magnetic Resonance Imaging (MRI) and CT imaging capability of the composite material, so that the nano particles and the composite material thereof have the imaging observation characteristic, and the observation of the material after bone implantation is facilitated. More importantly, the simultaneous doping of Cu and Gd can promote the adhesion of cells, is beneficial to the generation of calcium nodules of the cells and the osteogenic differentiation of the cells, and is further beneficial to bone repair.

Description

一种掺杂钙基材料、骨修复材料及其制备方法A calcium-doped material, bone repair material and preparation method thereof

技术领域technical field

本发明属于材料技术领域,具体涉及一种掺杂钙基材料、骨修复材料及其制备方法。The invention belongs to the technical field of materials, and in particular relates to a calcium-doped material, a bone repair material and a preparation method thereof.

背景技术Background technique

羟基磷灰石(HA)、β-磷酸三钙(β-TCP)、双相磷酸钙(BCP)等无机物因具有良好的生物相容性和成骨性能,而被单独或作为复合材料广泛应用于骨修复支架领域。但在感染性骨损伤、耐药的感染性骨损伤、及一些复杂骨损伤的免疫调控治疗方面,这些材料往往表现出功能相对单一的缺陷,仅仅能够起到结构性支撑和简单的成骨能力。Inorganic substances such as hydroxyapatite (HA), β-tricalcium phosphate (β-TCP), and biphasic calcium phosphate (BCP) are widely used alone or as composite materials because of their good biocompatibility and osteogenic properties. Applied in the field of bone repair bracket. However, in terms of infectious bone injury, drug-resistant infectious bone injury, and immunomodulatory treatment of some complex bone injuries, these materials often show relatively single-function defects, and can only provide structural support and simple osteogenesis. .

现有技术公开了多种对羟基磷灰石、β-磷酸三钙、双相磷酸钙等进行改性、掺杂等方式改善骨修复材料性能的技术,例如,在羟基磷灰石中掺杂稀土离子,提高羟基磷灰石的机械强度和韧性;或者在纳米羟基磷灰石中沉积纳米铜纳米氧化锌,增强其抗菌活性等。The prior art discloses a variety of technologies for improving the performance of bone repair materials by modifying and doping hydroxyapatite, β-tricalcium phosphate, biphasic calcium phosphate, etc., for example, doping hydroxyapatite Rare earth ions to improve the mechanical strength and toughness of hydroxyapatite; or deposit nano-copper nano-zinc oxide in nano-hydroxyapatite to enhance its antibacterial activity, etc.

发明内容Contents of the invention

有鉴于此,本申请的目的在于提供一种掺杂钙基材料、骨修复材料及其制备方法,本发明提供的骨修复材料具有免疫抗菌和成影像能力,同时能够促进细胞的粘附,有利于细胞钙结节产生和细胞的成骨分化,从而更有利于骨修复。In view of this, the purpose of this application is to provide a calcium-doped material, a bone repair material and a preparation method thereof. The bone repair material provided by the present invention has the ability of immunity, antibacterial and imaging, and can promote cell adhesion at the same time. It is conducive to the generation of calcium nodules and osteogenic differentiation of cells, which is more conducive to bone repair.

本发明提供了一种掺杂钙基材料,包括钙基材料和掺杂在所述钙基材料中的Cu和Gd,其中,Cu、Gd和钙基材料中的Ca的摩尔比为0.1~2:0.1~2:6~9.8。The present invention provides a doped calcium-based material, comprising calcium-based material and Cu and Gd doped in the calcium-based material, wherein the molar ratio of Cu, Gd and Ca in the calcium-based material is 0.1-2 :0.1~2:6~9.8.

本发明在钙基材料中同时添加Cu和Gd,其中,Cu元素具有显著的抗菌性能、抗炎性能和免疫调控性能,Gd元素的掺杂有助于提高复合材料的核磁(MRI)和CT成像能力,使纳米粒子及其复合材料具有影像学观察特征,有利于材料在骨骼植入后的观察。更重要的是,Cu和Gd的同时掺杂能够促进细胞的粘附,有利于细胞钙结节产生和细胞的成骨分化,从而更有利于骨修复。In the present invention, Cu and Gd are simultaneously added to the calcium-based material, wherein the Cu element has significant antibacterial properties, anti-inflammatory properties and immune regulation properties, and the doping of the Gd element helps to improve the nuclear magnetic (MRI) and CT imaging of the composite material The ability to make nanoparticles and their composite materials have imaging observation characteristics, which is conducive to the observation of materials after bone implantation. More importantly, the simultaneous doping of Cu and Gd can promote the adhesion of cells, which is beneficial to the generation of calcium nodules and osteogenic differentiation of cells, which is more conducive to bone repair.

在一个实施例中,所述钙基材料选自羟基磷灰石(HA)、β-磷酸三钙(β-TCP)和双相磷酸钙(BCP)中的一种或多种。In one embodiment, the calcium-based material is selected from one or more of hydroxyapatite (HA), β-tricalcium phosphate (β-TCP) and biphasic calcium phosphate (BCP).

在一个实施例中,Cu、Gd和钙基材料中的Ca的摩尔比为0.2~1.5:0.2~1.5:7~9.6。In one embodiment, the molar ratio of Cu, Gd and Ca in the calcium-based material is 0.2-1.5:0.2-1.5:7-9.6.

在一个实施例中,Cu、Gd和钙基材料中的Ca的摩尔比为0.5~1:0.5~1:8~9。In one embodiment, the molar ratio of Cu, Gd and Ca in the calcium-based material is 0.5˜1:0.5˜1:8˜9.

具体而言,Cu和Gd部分取代钙基材料中钙原子,当钙基材料为羟基磷灰石时,得到的掺杂材料分子式为:Specifically, Cu and Gd partially replace the calcium atoms in the calcium-based material. When the calcium-based material is hydroxyapatite, the molecular formula of the doped material obtained is:

Ca10-x-yCuxGdy(PO4)6(OH)2Ca 10-xy Cu x Gd y (PO 4 ) 6 (OH) 2 ;

其中,0.2≤x≤1.5,0.2≤y≤1.5。Among them, 0.2≤x≤1.5, 0.2≤y≤1.5.

当钙基材料为β-磷酸三钙时,得到的掺杂材料分子式为:When the calcium-based material is β-tricalcium phosphate, the molecular formula of the obtained doping material is:

Ca1.5-x-1.5yCuxGdy(PO4)2Ca 1.5-x-1.5y Cu x Gd y (PO 4 ) 2 ;

其中,0.2≤x≤1.5,0.2≤y≤1.5。Among them, 0.2≤x≤1.5, 0.2≤y≤1.5.

当钙基材料为双相钙磷盐或者双相磷酸钙时,Cu和Gd依然是取代其中的Ca。When the calcium-based material is a biphasic calcium phosphate or biphasic calcium phosphate, Cu and Gd still replace Ca.

本发明还提供了掺杂钙基材料的制备方法,包括:The present invention also provides a preparation method for doped calcium-based materials, including:

将钙盐、铜盐、钆盐和(NH4)2HPO3混合后进行反应,将得到的反应产物进行煅烧,得到掺杂钙基纳米材料;Calcium salt, copper salt, gadolinium salt and (NH 4 ) 2 HPO 3 are mixed and then reacted, and the obtained reaction product is calcined to obtain doped calcium-based nanomaterials;

其中,Cu、Gd和Ca的摩尔比为0.1~2:0.1~2:6~9.8。Wherein, the molar ratio of Cu, Gd and Ca is 0.1-2:0.1-2:6-9.8.

本发明通过水热法制备Cu和Gd掺杂的钙基材料,将钙盐、铜盐、钆盐和(NH4)2HPO3混合后进行反应,将得到的反应产物进行煅烧,得到掺杂钙基材料。The present invention prepares Cu and Gd-doped calcium-based materials by a hydrothermal method, mixes calcium salts, copper salts, gadolinium salts and (NH 4 ) 2 HPO 3 and reacts, and calcines the obtained reaction products to obtain doped Calcium-based materials.

在一个实施例中,钙盐选择硝酸钙、氯化钙中的一种或多种。In one embodiment, the calcium salt is selected from one or more of calcium nitrate and calcium chloride.

在一个实施例中,所述铜盐选自硝酸铜、氯化铜中的一种或多种。In one embodiment, the copper salt is selected from one or more of copper nitrate and copper chloride.

在一个实施例中,钆盐选自硝酸钆、氯化钆中的一种或多种。In one embodiment, the gadolinium salt is selected from one or more of gadolinium nitrate and gadolinium chloride.

在一个实施例中,所述反应在水浴锅中进行,反应的温度为40~80℃,时间为0.5~2h。在一个实施例中,所述反应的pH值为9~11。In one embodiment, the reaction is carried out in a water bath, the reaction temperature is 40-80°C, and the reaction time is 0.5-2h. In one embodiment, the pH of the reaction is 9-11.

反应完毕后,对所述反应产物进行煅烧,得到掺杂的钙基材料。在一个实施例中,所述煅烧的温度为180~200℃,时间为10~20h。After the reaction is completed, the reaction product is calcined to obtain a doped calcium-based material. In one embodiment, the temperature of the calcination is 180-200° C., and the time is 10-20 hours.

本发明提供的掺杂的钙基材料为纳米粒子,可以用于制备骨修复材料。The doped calcium-based material provided by the invention is a nano particle, which can be used to prepare a bone repair material.

本发明还提供了一种骨修复材料,包括上述技术方案所述的掺杂钙基材料和高分子材料。The present invention also provides a bone repair material, comprising the doped calcium-based material and the polymer material described in the above technical solution.

在一个实施例中,所述掺杂钙基材料和高分子材料的质量比为5~25:75~95。在一个实施例中,所述掺杂钙基材料和高分子材料的质量比为10~20:80~90。In one embodiment, the mass ratio of the doped calcium-based material to the polymer material is 5-25:75-95. In one embodiment, the mass ratio of the doped calcium-based material to the polymer material is 10-20:80-90.

在一个实施例中所述高分子材料选自聚乳酸、聚丙交酯-乙交酯(PLGA)或聚己内酯中的一种或多种。In one embodiment, the polymer material is selected from one or more of polylactic acid, polylactide-glycolide (PLGA) or polycaprolactone.

在一个实施例中,所述骨修复材料按照以下方法制备:In one embodiment, the bone repair material is prepared according to the following method:

将掺杂的钙基材料与第一有机溶剂中混合,得到第一混合液;mixing the doped calcium-based material with a first organic solvent to obtain a first mixed solution;

将高分子材料在第二溶剂中溶解,得到第二混合液;Dissolving the polymer material in a second solvent to obtain a second mixed solution;

将所述第一混合液和第二混合液混合后,在模具中冷冻,将冷冻后的骨修复材料在水中进行溶剂置换,冷冻干燥后得到具有特定形状的骨修复材料。After the first mixed liquid and the second mixed liquid are mixed, they are frozen in a mold, the frozen bone repair material is replaced with solvent in water, and the bone repair material with a specific shape is obtained after freeze-drying.

在一个实施例中,所述第一有机溶剂为丙酮,所述第二有机溶剂为N-甲基吡咯烷酮(NMP)。In one embodiment, the first organic solvent is acetone, and the second organic solvent is N-methylpyrrolidone (NMP).

在一个实施例中,冷冻的温度为-20~-80℃,冷冻的时间为6~24h。In one embodiment, the freezing temperature is -20 to -80° C., and the freezing time is 6 to 24 hours.

在一个实施例中,所述溶剂置换具体为:将冷冻后的骨修复材料浸泡在预冷的水中,使溶剂与水进行置换3~5天,每天换水2~3次,置换完成后,将得到的骨修复材料冷冻干燥成型即可。In one embodiment, the solvent replacement specifically includes: soaking the frozen bone repair material in pre-cooled water, replacing the solvent and water for 3-5 days, and changing the water 2-3 times a day. After the replacement, The obtained bone repair material can be freeze-dried and shaped.

本发明提供的骨修复材料具有免疫抗菌和成影像能力,同时能够促进细胞的粘附,有利于细胞钙结节产生和细胞的成骨分化,从而更有利于骨修复。The bone repair material provided by the invention has the ability of immunity, antibacterial and imaging, and can promote the adhesion of cells, which is beneficial to the generation of calcium nodules of cells and the osteogenic differentiation of cells, thereby being more beneficial to bone repair.

附图说明Description of drawings

图1为本发明实施例1制备的纳米粒子的SEM照片;Fig. 1 is the SEM photograph of the nanoparticle that the embodiment of the present invention 1 prepares;

图2为本发明比较例1制备的纳米粒子得到SEM照片;Fig. 2 obtains SEM photograph for the nanoparticle prepared by Comparative Example 1 of the present invention;

图3为本发明比较例2制备的纳米粒子得到SEM照片;Fig. 3 obtains the SEM photo for the nanoparticles prepared by Comparative Example 2 of the present invention;

图4为本发明比较例3制备的纳米粒子得到SEM照片;Fig. 4 obtains SEM photo for the nanoparticle prepared by Comparative Example 3 of the present invention;

图5为本发明实施例1及比较例制备的纳米粒子的XRD衍射图谱;Fig. 5 is the XRD diffraction pattern of the nanoparticle that the embodiment of the present invention 1 and comparative example prepare;

图6为本发明实施例1制备的纳米粒子的ICP分析结果;Fig. 6 is the ICP analysis result of the nanoparticle that the embodiment of the present invention 1 prepares;

图7为本发明比较例1制备的纳米粒子的ICP分析结果;Fig. 7 is the ICP analysis result of the nanoparticle that comparative example 1 of the present invention prepares;

图8为本发明比较例2制备的纳米粒子的ICP分析结果;Fig. 8 is the ICP analysis result of the nanoparticle that comparative example 2 of the present invention prepares;

图9为本发明比较例3制备的纳米粒子的ICP分析结果;Fig. 9 is the ICP analysis result of the nanoparticle that comparative example 3 of the present invention prepares;

图10为本发明实施例2及比较例制备的纳米粒子的FTIR图谱;Fig. 10 is the FTIR spectrum of the nanoparticles prepared by Example 2 and Comparative Example of the present invention;

图11为本发明实施例及比较例提供的复合材料支架的核磁显影照片;Fig. 11 is the nuclear magnetic imaging photograph of the composite material stent provided by the embodiment of the present invention and comparative example;

图12为本申请实施例2通过的复合材料支架不同用量时的核磁显影照片;Fig. 12 is the nuclear magnetic imaging photograph when the composite material stent adopted in Example 2 of the present application has different dosages;

图13为本发明实施例1制备的复合材料的染色细胞粘附结果;Figure 13 is the dyed cell adhesion result of the composite material prepared in Example 1 of the present invention;

图14为本发明比较例1制备的复合材料的染色细胞粘附结果;Fig. 14 is the dyed cell adhesion result of the composite material prepared in Comparative Example 1 of the present invention;

图15为本发明比较例2制备的复合材料的染色细胞粘附结果;Fig. 15 is the dyed cell adhesion result of the composite material prepared in Comparative Example 2 of the present invention;

图16为本发明比较例3制备的复合材料的染色细胞粘附结果;Fig. 16 is the dyed cell adhesion result of the composite material prepared in Comparative Example 3 of the present invention;

图17为本发明实施例1制备的复合材料的茜素红细胞钙结节染色结果;Fig. 17 is the staining result of the alizarin erythrocyte calcium nodule of the composite material prepared in Example 1 of the present invention;

图18为本发明比较例1制备的复合材料的茜素红细胞钙结节染色结果;Fig. 18 is the staining result of the alizarin erythrocyte calcium nodule of the composite material prepared in Comparative Example 1 of the present invention;

图19为本发明比较例2制备的复合材料的茜素红细胞钙结节染色结果;Fig. 19 is the staining result of the alizarin erythrocyte calcium nodule of the composite material prepared in comparative example 2 of the present invention;

图20为本发明比较例3制备的复合材料的茜素红细胞钙结节染色结果。Fig. 20 is the staining result of alizarin erythrocyte calcium nodules of the composite material prepared in Comparative Example 3 of the present invention.

具体实施方式Detailed ways

本申请通过实施例进一步说明掺杂的钙基材料、骨修复材料及其制备方法,然而,要理解的是,这些实施例不限制本发明。现在已知的或进一步开发的本发明的变化被认为落入本文中描述的和以下要求保护的本发明范围之内。The present application further illustrates the doped calcium-based material, bone repair material and preparation method thereof through examples, however, it should be understood that these examples do not limit the present invention. Variations of the invention now known or further developed are considered to fall within the scope of the invention described herein and claimed below.

实施例1Example 1

合成Cu/Gd共掺杂的羟基磷灰石纳米粒子:配置1M/L的Ca(NO3)2、CuCl2、Gd(NO3)3˙H2O液。调整Ca/Cu/Gd三者摩尔比例为9:0.5:0.5,添加上述溶液至(NH4)2HPO3中,在60℃水浴锅中搅拌,调节pH=10,反应持续1小时。反应结束后将反应产物加入反应釜中,180℃加热12小时,加热结束后自然冷却到室温,洗涤离心干燥得到纳米粒子(0.5Cu-0.5Gd-HA)。Synthesis of Cu/Gd co-doped hydroxyapatite nanoparticles: Prepare 1M/L Ca(NO 3 ) 2 , CuCl 2 , Gd(NO 3 ) 3 ˙H 2 O solution. Adjust the molar ratio of Ca/Cu/Gd to 9:0.5:0.5, add the above solution to (NH 4 ) 2 HPO 3 , stir in a water bath at 60°C, adjust the pH to 10, and continue the reaction for 1 hour. After the reaction, the reaction product was added into the reaction kettle, heated at 180° C. for 12 hours, naturally cooled to room temperature after the heating, washed, centrifuged and dried to obtain nanoparticles (0.5Cu-0.5Gd-HA).

制备双掺杂0.5Cu-0.5Gd-HA与PLGA的复合材料(0.5Cu-0.5Gd-HA与PLGA的质量比为10:90):称取Cu-Gd-HA,加入丙酮中超声搅拌混匀;称取PLGA,利用N-甲基吡咯烷酮(NMP)充分溶解,混合上述两种溶液,混合液移入注射器中,-80℃冷冻20h。剪去前段带针头部位,将材料推注入预冷的去离子水中,使溶剂与水置换3-5天,每天换水2-3次。支架置换结束后,取出冷冻干燥后即可成型,得到支架状骨修复材料。Preparation of double-doped 0.5Cu-0.5Gd-HA and PLGA composite material (the mass ratio of 0.5Cu-0.5Gd-HA to PLGA is 10:90): Weigh Cu-Gd-HA, add it into acetone and mix it with ultrasonic ; Weigh PLGA, fully dissolve with N-methylpyrrolidone (NMP), mix the above two solutions, transfer the mixture into a syringe, and freeze at -80°C for 20h. Cut off the front section with needles, push the material into pre-cooled deionized water, replace the solvent and water for 3-5 days, and change the water 2-3 times a day. After the replacement of the scaffold, it can be molded after being taken out and freeze-dried to obtain a scaffold-like bone repair material.

实施例2Example 2

与实施例1的区别在于,调整Ca/Cu/Gd三者摩尔比例为8:1:1。The difference from Example 1 is that the molar ratio of Ca/Cu/Gd is adjusted to be 8:1:1.

比较例1Comparative example 1

与实施例1的区别在于,不掺杂Cu和Gd。The difference from Example 1 is that Cu and Gd are not doped.

比较例2Comparative example 2

与实施例1的区别在于,调整Ca/Cu摩尔比例为9.5:0.5,不掺杂Gd。The difference from Example 1 is that the molar ratio of Ca/Cu is adjusted to 9.5:0.5, and Gd is not doped.

比较例3Comparative example 3

与实施例1的区别在于,调整Ca/Gd摩尔比例为9.5:0.5,不掺杂Cu。The difference from Example 1 is that the molar ratio of Ca/Gd is adjusted to 9.5:0.5, and Cu is not doped.

比较例4Comparative example 4

与实施例2的区别在于,调整Ca/Cu摩尔比例为9:1,不掺杂Gd。The difference from Example 2 is that the molar ratio of Ca/Cu is adjusted to 9:1, and Gd is not doped.

比较例5Comparative Example 5

与实施例1的区别在于,调整Ca/Gd摩尔比例为9:1,不掺杂Cu。The difference from Example 1 is that the molar ratio of Ca/Gd is adjusted to 9:1, and Cu is not doped.

对实施例1、比较例1~3制备的纳米粒子进行SEM表征,结果参见图1、图2、图3、图4,图1为本发明实施例1制备的纳米粒子的SEM照片,其中,图1(A)是500nm标尺下的SEM照片,图1(B)是200nm标尺下的SEM照片;图2为本发明比较例1制备的纳米粒子得到SEM照片,其中,图2(A)是500nm标尺下的SEM照片,图2(B)是200nm标尺下的SEM照片;图3为本发明比较例2制备的纳米粒子得到SEM照片,其中,图3(A)是500nm标尺下的SEM照片,图3(B)是200nm标尺下的SEM照片;图4为本发明比较例3制备的纳米粒子得到SEM照片,其中,图4(A)是500nm标尺下的SEM照片,图4(B)是200nm标尺下的SEM照片。由图1~图4可知,所制备的HA及掺杂了Cu或/和Gd的Cu-HA、Gd-HA、Cu-Gd-HA均为短棒状结构,表明元素掺杂并没有改变纳米粒子的微观形貌。The nanoparticles prepared in Example 1 and Comparative Examples 1 to 3 were characterized by SEM, the results are shown in Fig. 1, Fig. 2, Fig. 3 and Fig. 4, and Fig. 1 is a SEM photo of the nanoparticles prepared in Example 1 of the present invention, wherein, Fig. 1 (A) is the SEM photograph under the 500nm scale, and Fig. 1 (B) is the SEM photograph under the 200nm scale; Fig. 2 obtains the SEM photograph for the nanoparticle prepared by Comparative Example 1 of the present invention, wherein, Fig. 2 (A) is The SEM photograph under the 500nm scale, Fig. 2 (B) is the SEM photograph under the 200nm scale; Fig. 3 obtains the SEM photograph for the nanoparticles prepared in Comparative Example 2 of the present invention, wherein, Fig. 3 (A) is the SEM photograph under the 500nm scale , Fig. 3 (B) is the SEM photo under the 200nm scale; Fig. 4 obtains the SEM photo for the nanoparticles prepared in Comparative Example 3 of the present invention, wherein, Fig. 4 (A) is the SEM photo under the 500nm scale, Fig. 4 (B) It is the SEM picture under 200nm scale. From Figures 1 to 4, it can be seen that the prepared HA and Cu-HA, Gd-HA, and Cu-Gd-HA doped with Cu or/and Gd are all short rod-shaped structures, indicating that element doping does not change the nanoparticle microscopic morphology.

对实施例1、比较例1~3制备的纳米粒子进行X射线衍射图谱分析,结果参见图5,图5为本发明实施例1及比较例制备的纳米粒子的XRD衍射图谱,其中,自下而上分别为比较例1、比较例2、比较例3和实施例1制备的纳米粒子的XRD衍射图谱。由图5可知,HA具备典型的晶体特征峰,三强峰的位置分别在25.8°、31.7°、32.9°三处。而掺杂的HA因为外来离子的引入会导致HA的晶格出现变换,表现在XRD上的结果为峰位置、峰的宽窄、峰的大小等轻微变化。Carry out X-ray diffraction pattern analysis to the nanoparticles prepared in Example 1 and Comparative Examples 1 to 3, the results are shown in Fig. 5, Fig. 5 is the XRD diffraction pattern of the nanoparticles prepared in Example 1 and Comparative Example of the present invention, wherein, from the following The above are the XRD diffraction patterns of the nanoparticles prepared in Comparative Example 1, Comparative Example 2, Comparative Example 3 and Example 1 respectively. It can be seen from Figure 5 that HA has typical crystal characteristic peaks, and the positions of the three strong peaks are at 25.8°, 31.7°, and 32.9° respectively. The introduction of foreign ions in doped HA will cause the crystal lattice of HA to change, and the results shown in XRD are slight changes in peak position, peak width, and peak size.

对实施例1、比较例1~3制备的纳米粒子元素组成分析,结果参见图6、图7、图8、图9,图6为本发明实施例1制备的纳米粒子的ICP分析结果,其中,Ca含量为60.9%,P含量为29.4%,Gd含量为9%,Cu含量为0.7%;图7为本发明比较例1制备的纳米粒子的ICP分析结果,其中,Ca含量为70.6%,P含量为29.4%,Gd含量为0%,Cu含量为0%;图8为本发明比较例2制备的纳米粒子的ICP分析结果,其中,Ca含量为67.1%,P含量为31.1%,Gd含量为0%,Cu含量为1.8%;图9为本发明比较例3制备的纳米粒子的ICP分析结果,其中,Ca含量为60.2%,P含量为30.3%,Gd含量为9.5%,Cu含量为0%。由图6~图9可知,本发明提供的方法获得了铜元素和钆元素掺杂的羟基磷灰石纳米粒子。For the analysis of the elemental composition of the nanoparticles prepared in Example 1 and Comparative Examples 1 to 3, the results are shown in Fig. 6, Fig. 7, Fig. 8, and Fig. 9. Fig. 6 is the ICP analysis result of the nanoparticles prepared in Example 1 of the present invention, wherein , the Ca content is 60.9%, the P content is 29.4%, the Gd content is 9%, and the Cu content is 0.7%. The P content is 29.4%, the Gd content is 0%, and the Cu content is 0%. content is 0%, Cu content is 1.8%; Fig. 9 is the ICP analysis result of the nanoparticle prepared in Comparative Example 3 of the present invention, wherein, Ca content is 60.2%, P content is 30.3%, Gd content is 9.5%, Cu content is 0%. It can be known from FIGS. 6 to 9 that the method provided by the present invention obtains hydroxyapatite nanoparticles doped with copper and gadolinium.

对实施例2、比较例1、比较例4和5的复合材料进行红外分析,结果参见图10,图10为本发明实施例2及比较例制备的纳米粒子的FTIR图谱,其中,自上而下分别为比较例1、比较例5、比较例4和实施例2制备的纳米粒子的FTIR图谱。由图10可知,样品在不同波长处出现了不同基团的吸收峰,在3445cm-1和1420cm-1附近出现吸收峰,对应于-OH羟基的伸缩振动和弯曲振动,表明样品中存在-OH。在565cm-1和607cm-1处的吸收峰符合O-P-O的弯曲振动模式,证明材料中存在磷酸根基团。而在1038cm-1出现的强吸收峰起因于P-O反对称伸缩振动模式。这些官能团的位置与文献中报道的HA的红外吸收峰波长吻合,并且无其他杂峰,表明产品中存在主要基团为羟基与磷酸根基团,符合HA的红外吸收光谱结果。掺杂以后无明显变化。Carry out infrared analysis to the composite material of embodiment 2, comparative example 1, comparative example 4 and 5, see Fig. 10 for the result, Fig. 10 is the FTIR collection of illustrative plates of the nanoparticles prepared by embodiment 2 of the present invention and comparative example, wherein, from top to bottom The following are the FTIR spectra of the nanoparticles prepared in Comparative Example 1, Comparative Example 5, Comparative Example 4 and Example 2 respectively. It can be seen from Figure 10 that the sample has absorption peaks of different groups at different wavelengths, and the absorption peaks appear around 3445cm -1 and 1420cm -1 , corresponding to the stretching vibration and bending vibration of the -OH hydroxyl group, indicating the presence of -OH in the sample . The absorption peaks at 565 cm -1 and 607 cm -1 fit the bending vibration mode of OPO, proving the presence of phosphate groups in the material. And the strong absorption peak at 1038cm -1 originates from the PO antisymmetric stretching vibration mode. The position of these functional groups is consistent with the infrared absorption peak wavelength of HA reported in the literature, and there are no other miscellaneous peaks, indicating that the main groups in the product are hydroxyl and phosphate groups, which is consistent with the infrared absorption spectrum results of HA. There was no significant change after doping.

将实施例1~2、比较例1~3、比较例5制备得到的复合材料支架进行核磁MRI成影像测试,将各组支架材料放入含PBS的样品管,加入量为20%,置入1.2T核磁显影仪,拍照,结果参见图11,图11为本发明实施例及比较例提供的复合材料支架的核磁显影照片;将实施例2制备的1Cu-1Gd-HA含量分别为5%、10%、20%和40%的复合材料支架加入到含PBS的样品管中,置入1.2T核磁显影仪,拍照,结果参见图12,图12为本申请实施例2提供的复合材料不同用量时的核磁显影照片。图11表明掺杂0.5Gd-HA和1Gd-HA可明显提高材料的核磁MRI成像能力,图12表明加入了5%、10%、20%和40%不同百分含量的1Cu-1Gd-HA时其成像效果具有明显的梯度区别,表明制备的复合材料在核磁MRI成像、及持续观察方面具有潜在优势。The composite material brackets prepared in Examples 1-2, Comparative Examples 1-3, and Comparative Example 5 were subjected to NMR imaging tests, and each group of bracket materials was put into a sample tube containing PBS, and the addition amount was 20%. 1.2T nuclear magnetic developing apparatus, take pictures, the result is referring to Fig. 11, and Fig. 11 is the nuclear magnetic developing photograph of the composite material support that the embodiment of the present invention and comparative example provide; 10%, 20% and 40% of the composite material support were added to the sample tube containing PBS, placed in a 1.2T nuclear magnetic imaging apparatus, and photographed, the results are shown in Figure 12, Figure 12 shows the different dosages of the composite material provided in Example 2 of the present application MRI photographs at the time. Figure 11 shows that doping 0.5Gd-HA and 1Gd-HA can significantly improve the nuclear magnetic MRI imaging ability of the material, and Figure 12 shows that when 5%, 10%, 20% and 40% of 1Cu-1Gd-HA with different percentages are added The imaging effect has obvious gradient difference, indicating that the prepared composite material has potential advantages in nuclear magnetic MRI imaging and continuous observation.

实施例3Example 3

首先制备复合材料薄膜用于细胞培养:First prepare the composite film for cell culture:

称取一定量的PLGA溶于三氯甲烷,配制成10%(w/v)的溶液,充分溶解后,将实施例1~2和对比例1~5制备的纳米粒子按照纳米粒子:PLGA=10:90的比例分散于溶液中,磁力搅拌辅以超声处理。取经二甲二氯硅烷(DMDC)硅化处理过的盖玻片,将HA/PLGA复合材料溶液涂于玻片上,置于细胞培养板,真空干燥除去溶剂后,形成HA/PLGA复合材料薄膜,75%乙醇消毒,PBS清洗备用。Take a certain amount of PLGA and be dissolved in chloroform, be mixed with a 10% (w/v) solution, after fully dissolving, the nanoparticles prepared in Examples 1~2 and Comparative Examples 1~5 are according to the nanoparticle: PLGA= The ratio of 10:90 is dispersed in the solution, magnetic stirring is supplemented by ultrasonic treatment. Take the cover glass that has been siliconized with dimethyldichlorosilane (DMDC), apply the HA/PLGA composite solution on the glass slide, place it on a cell culture plate, and dry it in vacuum to remove the solvent to form a HA/PLGA composite film, 75 Sterilize with % ethanol and wash with PBS for later use.

小鼠成骨前体细胞MC3T3-E1以2.0×104/mL密度接种于复合材料薄膜上,于37℃,5%CO2孵箱培养。培养24h后,PBS清洗三次;4%多聚甲醛固定10min,PBS清洗三次;FITC(异硫氰酸荧光素)染色10min,PBS清洗三次。荧光显微镜观察、拍照。结果参见图13、图14、图15和图16,图13为本发明实施例1制备的复合材料的染色细胞粘附结果;图14为本发明比较例1制备的复合材料的染色细胞粘附结果;图15为本发明比较例2制备的复合材料的染色细胞粘附结果;图16为本发明比较例3制备的复合材料的染色细胞粘附结果。由图13~16可知,本发明制备的复合材料可促进细胞粘附。Mouse osteoblast precursor cells MC3T3-E1 were seeded on the composite film at a density of 2.0×10 4 /mL, and cultured in a 5% CO 2 incubator at 37°C. After culturing for 24 hours, wash with PBS three times; fix with 4% paraformaldehyde for 10 minutes, wash with PBS three times; stain with FITC (fluorescein isothiocyanate) for 10 minutes, and wash with PBS for three times. Fluorescence microscope observation and photographing. Refer to Figure 13, Figure 14, Figure 15 and Figure 16 for the results, Figure 13 is the stained cell adhesion result of the composite material prepared in Example 1 of the present invention; Figure 14 is the stained cell adhesion result of the composite material prepared in Comparative Example 1 of the present invention Results; Figure 15 is the stained cell adhesion result of the composite material prepared in Comparative Example 2 of the present invention; Figure 16 is the stained cell adhesion result of the composite material prepared in Comparative Example 3 of the present invention. It can be known from Figures 13-16 that the composite material prepared by the present invention can promote cell adhesion.

细胞培养到14和21天,细胞使用PBS清洗三次,4%多聚甲醛室温固定10min,PBS清洗三次,茜素红(ARS)染液(0.1%ARS的Tris·HCl溶液,pH=8.0)孵育30min,再清洗三次。使用显微镜观察、拍照。结果参见图17~图20,其中,图17为本发明实施例1制备的复合材料的茜素红细胞钙结节染色结果,其中,图17(A)是14天染色结果,图17(B)是21天染色结果;图18为本发明比较例1制备的复合材料的茜素红细胞钙结节染色结果,其中,图18(A)是14天染色结果,图18(B)是21天染色结果;图19为本发明比较例2制备的复合材料的茜素红细胞钙结节染色结果,其中,图19(A)是14天染色结果,图19(B)是21天染色结果;图20为本发明比较例3制备的复合材料的茜素红细胞钙结节染色结果,其中,图20(A)是14天染色结果,图20(B)是21天染色结果。由图17~图20可知,掺杂元素有利于细胞钙结节产生,即利于矿化,表明有利于细胞的成骨分化。After the cells were cultured for 14 and 21 days, the cells were washed three times with PBS, fixed with 4% paraformaldehyde at room temperature for 10 min, washed three times with PBS, and incubated with Alizarin Red (ARS) staining solution (0.1% ARS in Tris·HCl solution, pH=8.0) 30min, and then washed three times. Use a microscope to observe and take pictures. The results are shown in Figures 17 to 20, wherein Figure 17 shows the staining results of alizarin erythrocyte calcium nodules of the composite material prepared in Example 1 of the present invention, wherein Figure 17(A) is the staining result after 14 days, and Figure 17(B) It is the dyeing result in 21 days; Fig. 18 is the alizarin erythrocyte calcium nodule staining result of the composite material prepared in Comparative Example 1 of the present invention, wherein, Fig. 18 (A) is the staining result in 14 days, and Fig. 18 (B) is the staining result in 21 days Result; Fig. 19 is the alizarin erythrocyte calcium nodule staining result of the composite material prepared in comparative example 2 of the present invention, wherein, Fig. 19 (A) is the staining result in 14 days, and Fig. 19 (B) is the staining result in 21 days; Fig. 20 Alizarin erythrocyte calcium nodule staining results of the composite material prepared for Comparative Example 3 of the present invention, wherein, Fig. 20(A) is the staining result on day 14, and Fig. 20(B) is the staining result on day 21. It can be known from Figures 17 to 20 that doping elements are beneficial to the generation of calcium nodules in cells, that is, beneficial to mineralization, indicating that they are beneficial to osteogenic differentiation of cells.

本发明内容仅仅举例说明了要求保护的一些具体实施方案,其中一个或更多个技术方案中所记载的技术特征可以与任意的一个或多个技术方案相组合,这些经组合而得到的技术方案也在本申请保护范围内,就像这些经组合而得到的技术方案已经在本发明公开内容中具体记载一样。The summary of the present invention only exemplifies some specific embodiments of the claims, wherein the technical features recorded in one or more technical solutions can be combined with any one or more technical solutions, and the technical solutions obtained by these combinations It is also within the scope of protection of the present application, just as these combined technical solutions have been specifically recorded in the disclosure content of the present invention.

Claims (10)

1. A doped calcium-based material comprises a calcium-based material and Cu and Gd doped in the calcium-based material, wherein the charging molar ratio of the Cu to the Gd to Ca in the calcium-based material is 0.1-2, and the charging molar ratio of the Cu to the Gd to Ca in the calcium-based material is 0.1-2:6-9.8.
2. The doped calcium-based material according to claim 1, wherein said calcium-based material is selected from one or more of hydroxyapatite, β -tricalcium phosphate and biphasic calcium phosphate.
3. The calcium-doped base material according to claim 2, wherein the molar ratio of Cu, gd, and Ca in the calcium-based material is 0.2 to 1.5.
4. The doped calcium-based material of claim 3, wherein the molar ratio of Cu, gd, and Ca in the calcium-based material is from 0.5 to 1.
5. A bone repair material comprising the doped calcium-based material of any one of claims 1 to 4 and a polymeric material.
6. The bone repair material according to claim 5, wherein the mass ratio of the doped calcium-based material to the polymer material is 5 to 25.
7. The bone repair material according to claim 6, wherein the polymeric material is selected from one or more of polylactic acid, polylactide-glycolide or polycaprolactone.
8. A method of preparing a doped calcium-based material, comprising:
mixing calcium salt, copper salt, gadolinium salt and (NH) 4 ) 2 HPO 3 Mixing, reacting, and calcining the obtained reaction product to obtain the doped calcium-based nano material;
wherein the molar ratio of Cu, gd and Ca is 0.1-2:6-9.8.
9. The preparation method according to claim 8, wherein the reaction temperature is 40-80 ℃ and the reaction time is 0.5-2 h.
10. The preparation method according to claim 9, wherein the calcination is carried out at a temperature of 180 to 200 ℃ for 10 to 20 hours.
CN202111659702.7A 2021-12-30 2021-12-30 Calcium-doped material, bone repair material and preparation method thereof Active CN114699561B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111659702.7A CN114699561B (en) 2021-12-30 2021-12-30 Calcium-doped material, bone repair material and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111659702.7A CN114699561B (en) 2021-12-30 2021-12-30 Calcium-doped material, bone repair material and preparation method thereof

Publications (2)

Publication Number Publication Date
CN114699561A CN114699561A (en) 2022-07-05
CN114699561B true CN114699561B (en) 2023-03-31

Family

ID=82167541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111659702.7A Active CN114699561B (en) 2021-12-30 2021-12-30 Calcium-doped material, bone repair material and preparation method thereof

Country Status (1)

Country Link
CN (1) CN114699561B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942396A (en) * 2004-03-15 2007-04-04 苏黎世联合高等工业学校 Flame synthesis of metal salt manoparticles, in particular calcium and phosphate comprising nanoparticles
CN106823008A (en) * 2016-12-30 2017-06-13 北京爱康宜诚医疗器材有限公司 Bone renovating material and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199005B2 (en) * 2003-10-01 2015-12-01 New York University Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate
EP1687034A1 (en) * 2003-11-17 2006-08-09 Philips Intellectual Property & Standards GmbH Contrast agent for medical imaging techniques and usage thereof
SA114350273B1 (en) * 2009-04-21 2016-06-23 امونولايت، ال ال سي Non-invasive energy upconversion methods and systems for in-situ photobiomodulation
CN104059661A (en) * 2013-03-20 2014-09-24 海洋王照明科技股份有限公司 Metal nanoparticles-doped gadolinium acid calcium luminescent material and preparation method thereof
SI3331580T1 (en) * 2015-08-06 2020-03-31 GreenBone Ortho S.r.l. Large 3d porous scaffolds made of active hydroxyapatite obtained by biomorphic transformation of natural structures and process for obtaining them
CN109704350A (en) * 2017-10-26 2019-05-03 中国石油化工股份有限公司 Adulterate apatite-type lanthanum silicate and its preparation method and application in lanthanum position
CN108129048B (en) * 2018-02-09 2020-06-23 河南科技大学 A kind of temperature-controlled magnetocaloric bone cement that can be heated rapidly and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942396A (en) * 2004-03-15 2007-04-04 苏黎世联合高等工业学校 Flame synthesis of metal salt manoparticles, in particular calcium and phosphate comprising nanoparticles
CN106823008A (en) * 2016-12-30 2017-06-13 北京爱康宜诚医疗器材有限公司 Bone renovating material and preparation method thereof

Also Published As

Publication number Publication date
CN114699561A (en) 2022-07-05

Similar Documents

Publication Publication Date Title
Fabbri et al. Porous scaffolds of polycaprolactone reinforced with in situ generated hydroxyapatite for bone tissue engineering
Zhao et al. Gadolinium phosphate/chitosan scaffolds promote new bone regeneration via Smad/Runx2 pathway
Luo et al. Injectable self-healing anti-inflammatory europium oxide-based dressing with high angiogenesis for improving wound healing and skin regeneration
John et al. Designing of macroporous magnetic bioscaffold based on functionalized methacrylate network covered by hydroxyapatites and doped with nano-MgFe2O4 for potential cancer hyperthermia therapy
Zheng et al. Preparation of bioactive hydroxyapatite@ halloysite and its effect on MC3T3-E1 osteogenic differentiation of chitosan film
CN107265426B (en) template-mediated synthesis of silicon-containing hydroxyapatite material and preparation method thereof
CN111849013A (en) A nano-hydroxyapatite-silk fibroin mineralized scaffold and its preparation method and use
CN114634608B (en) Shape memory polyurethane and self-reinforced regular pore polymer film prepared from same
CN102908664B (en) Apatite/keratin composite scaffold and preparation method thereof
CN107789674B (en) Preparation method of composite biological membrane material with porous microsphere structure, product and application thereof
Fan et al. Preparation and properties of g-TTCP/PBS nanocomposites and its in vitro biocompatibility assay
CN101148778A (en) Hydroxyapatite whiskers with high aspect ratio and preparation method thereof
CN102085391A (en) Hydroxyapatite/chitosan-silk fibroin nanocomposite and preparation method thereof
CN103656756B (en) Nano-hydroxyapatite/silk fibroin composite membrane material and preparation method thereof
CN114699561B (en) Calcium-doped material, bone repair material and preparation method thereof
Duan et al. Effect of SiO2 in situ cross-linked CS/PVA on SrFe12O19 scaffolds prepared by 3D gel printing for targeting
WO2018019208A1 (en) Novel formula for synthesizing bone replacement material, and manufacturing method and application method thereof
CN107973329B (en) A kind of preparation method of short prismatic α-calcium sulfate hemihydrate powder
Mayeen et al. Flexible, electrospun boron nitride nanosheets (BNNS)/hydroxyapatite–PVDF nanofibers with superior piezoelectric/ferroelectric, biocompatible features for effective bone tissue regeneration
Ma et al. Preparation and properties of biomimetic hydroxyapatite-based nanocomposite utilizing bamboo fiber
CN109568675A (en) Degradation rate can fluorescent marker the preparation of polyester/periodic mesoporous bone filled composite materials and product and application
Jia et al. Fabrication and characterization of chitosan/mesoporous bioactive glasses porous films
Wu et al. Fabrication of Gd/Eu-codoped SmPO4 nanorods for dual-modal magnetic resonance and bio-optical imaging
CN110354313B (en) Magnetic reinforcing phase modified composite material and preparation method thereof
CN101979312B (en) Hydroxylapatite bionic structure material and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant